OLFML3

Summary

OLFML3 (olfactomedin like 3, HGNC:24956) is a protein-coding gene on chromosome 1p13.2, encoding Olfactomedin-like protein 3 (Q9NRN5). Secreted scaffold protein that plays an essential role in dorsoventral patterning during early development. It is a selective cancer dependency (DepMap: 27.9% of cell lines).

This gene encodes a member of the olfactomedin-like gene family which also includes genes encoding noelin, tiarin, myocilin, amassin, optimedin, photomedin, and latrophilin. The encoded protein is a secreted extracellular matrix glycoprotein with a C-terminal olfactomedin domain that facilitates protein-protein interactions, cell adhesion, and intercellular interactions. It serves as both a scaffold protein that recruits bone morphogenetic protein 1 to its substrate chordin, and as a vascular tissue remodeler with pro-angiogenic properties. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 56944 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 72 total
• Cancer dependency (DepMap): dependent in 27.9% of screened cell lines
• MANE Select transcript: NM_020190

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24956
Approved symbol	OLFML3
Name	olfactomedin like 3
Location	1p13.2
Locus type	gene with protein product
Status	Approved
Aliases	HNOEL-iso, OLF44
Ensembl gene	ENSG00000116774
Ensembl biotype	protein_coding
OMIM	610088
Entrez	56944

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000320334, ENST00000369551, ENST00000393300, ENST00000491700, ENST00000633022, ENST00000854415, ENST00000933255

RefSeq mRNA: 3 — MANE Select: NM_020190 NM_001286352, NM_001286353, NM_020190

CCDS: CCDS65618, CCDS72839, CCDS870

Canonical transcript exons

ENST00000320334 — 3 exons

Exon	Start	End
ENSE00000784440	113980332	113980617
ENSE00000800065	113979474	113979630
ENSE00003841814	113980949	113982253

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 97.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 61.9543 / max 2433.2607, expressed in 1234 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4748	61.6798	1234
4751	0.2745	130

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gall bladder	UBERON:0002110	97.81	gold quality
left uterine tube	UBERON:0001303	97.71	gold quality
body of uterus	UBERON:0009853	97.66	gold quality
right ovary	UBERON:0002118	97.64	gold quality
placenta	UBERON:0001987	97.43	gold quality
calcaneal tendon	UBERON:0003701	97.43	gold quality
ovary	UBERON:0000992	97.39	gold quality
left ovary	UBERON:0002119	97.39	gold quality
endocervix	UBERON:0000458	97.37	gold quality
smooth muscle tissue	UBERON:0001135	97.23	gold quality
myometrium	UBERON:0001296	96.81	gold quality
stromal cell of endometrium	CL:0002255	96.39	gold quality
fallopian tube	UBERON:0003889	96.14	gold quality
omental fat pad	UBERON:0010414	95.57	gold quality
vagina	UBERON:0000996	95.34	gold quality
ectocervix	UBERON:0012249	95.31	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.91	gold quality
uterine cervix	UBERON:0000002	94.82	gold quality
mucosa of stomach	UBERON:0001199	94.20	gold quality
endometrium	UBERON:0001295	94.06	gold quality
urinary bladder	UBERON:0001255	93.95	gold quality
adipose tissue	UBERON:0001013	93.92	gold quality
right lung	UBERON:0002167	93.59	gold quality
right atrium auricular region	UBERON:0006631	93.46	gold quality
lung	UBERON:0002048	93.23	gold quality
upper lobe of left lung	UBERON:0008952	93.06	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.02	gold quality
thoracic mammary gland	UBERON:0005200	92.96	gold quality
fundus of stomach	UBERON:0001160	92.92	gold quality
ascending aorta	UBERON:0001496	92.80	gold quality

Single-cell (SCXA)

Detected in 19 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-MTAB-7008	yes	450.59
E-MTAB-10287	yes	129.78
E-MTAB-6701	yes	115.04
E-HCAD-1	yes	79.04
E-HCAD-10	yes	75.50
E-MTAB-8410	yes	57.99
E-GEOD-135922	yes	57.42
E-HCAD-4	yes	19.18
E-CURD-112	yes	15.48
E-HCAD-13	yes	13.79
E-GEOD-81547	yes	9.75
E-MTAB-10042	yes	8.10
E-MTAB-9388	yes	6.67
E-GEOD-84465	yes	6.29
E-MTAB-10553	yes	5.65

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting OLFML3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-155-5P	99.35	70.16	1509
HSA-MIR-7515	99.31	68.22	1795
HSA-MIR-4293	99.22	65.46	1263
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-491-5P	99.13	65.98	1468
HSA-MIR-6871-5P	98.90	66.67	671
HSA-MIR-5000-3P	98.79	65.63	1251
HSA-MIR-4722-5P	98.46	66.34	1611
HSA-MIR-624-3P	98.37	67.06	1067
HSA-MIR-4684-3P	98.24	69.91	1075
HSA-MIR-541-5P	98.24	67.77	1181
HSA-MIR-510-5P	97.66	65.82	916
HSA-MIR-3928-3P	97.61	66.53	1096
HSA-MIR-4727-3P	96.75	64.97	415
HSA-MIR-6822-3P	96.60	66.06	680
HSA-MIR-6750-5P	93.94	66.68	797
HSA-MIR-6822-5P	93.94	66.34	812

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 27.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• may have matrix-related function involved in human placental and embryonic development, or play a similar role in other physiological processes (PMID:15280020)
• This paper reports OLFML3 expression in human and baboon eye. The full coding DNA sequence has 1221 bp, from which an open reading frame of 406 amino acid was obtained. (PMID:23398349)
• Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment. (PMID:31919052)
• Surfaceome CRISPR screen identifies OLFML3 as a rhinovirus-inducible IFN antagonist. (PMID:34686207)
• Microglia-Derived Olfactomedin-like 3 Promotes Pro-Tumorigenic Microglial Function and Malignant Features of Glioma Cells. (PMID:34884869)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	olfml3a	ENSDARG00000061852
danio_rerio	olfml3b	ENSDARG00000062171
mus_musculus	Olfml3	ENSMUSG00000027848
rattus_norvegicus	Olfml3	ENSRNOG00000019211

Paralogs (9): MYOC (ENSG00000034971), OLFM4 (ENSG00000102837), OLFM2 (ENSG00000105088), OLFM3 (ENSG00000118733), OLFM1 (ENSG00000130558), OLFML2B (ENSG00000162745), OLFML1 (ENSG00000183801), OLFML2A (ENSG00000185585), GLDN (ENSG00000186417)

Protein

Protein identifiers

Olfactomedin-like protein 3 — Q9NRN5 (reviewed: Q9NRN5)

Alternative names: HNOEL-iso, hOLF44

All UniProt accessions (3): Q9NRN5, B4DNG0, M1LAK4

UniProt curated annotations — full annotation on UniProt →

Function. Secreted scaffold protein that plays an essential role in dorsoventral patterning during early development. Stabilizes axial formation by restricting chordin (CHRD) activity on the dorsal side. Acts by facilitating the association between the tolloid proteases and their substrate chordin (CHRD), leading to enhance chordin (CHRD) degradation. May have matrix-related function involved in placental and embryonic development, or play a similar role in other physiological processes.

Subcellular location. Secreted.

Tissue specificity. Abundant in placenta, moderate in liver and heart, whereas fairly weak in other tissues examined. On term placenta, mainly localized extracellularly surrounding the syncytiotrophoblastic cells and very rarely expressed in the maternal decidua layer.

Similarity. Belongs to the OLFML3 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NRN5-1	1	yes
Q9NRN5-2	2
Q9NRN5-3	3

RefSeq proteins (3): NP_001273281, NP_001273282, NP_064575* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003112	Olfac-like_dom	Domain
IPR050605	Olfactomedin-like_domain	Family

Pfam: PF02191

UniProt features (15 total): splice variant 4, sequence conflict 4, glycosylation site 2, signal peptide 1, chain 1, domain 1, coiled-coil region 1, disulfide bond 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NRN5-F1	87.21	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 135–328

Glycosylation sites (2): 177, 248

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 163 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, E2F4DP1_01, XU_GH1_AUTOCRINE_TARGETS_UP, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, TERAMOTO_OPN_TARGETS_CLUSTER_6, E2F_Q3, GATA6_01, ONDER_CDH1_TARGETS_2_UP, AACTTT_UNKNOWN, BENPORATH_NOS_TARGETS, DOUGLAS_BMI1_TARGETS_UP, DBP_Q6, RIGGI_EWING_SARCOMA_PROGENITOR_UP, DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_DN, YNGTTNNNATT_UNKNOWN

GO Biological Process (1): signal transduction (GO:0007165)

GO Molecular Function (0):

GO Cellular Component (3): obsolete extracellular space (GO:0005615), extracellular vesicle (GO:1903561), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
extracellular region	1
vesicle	1
extracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

880 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OLFML3	TMEM119	Q4V9L6	742
OLFML3	P2RY12	Q9H244	733
OLFML3	GPR34	Q9UPC5	678
OLFML3	SALL1	Q9NSC2	571
OLFML3	P2RY13	Q9BPV8	500
OLFML3	TREM2	Q9NZC2	500
OLFML3	BMP4	P12644	493
OLFML3	CX3CR1	P49238	487
OLFML3	CSF1R	P07333	480
OLFML3	TGFBR1	P36897	444
OLFML3	RSBN1	Q5VWQ0	438
OLFML3	DENND2C	Q68D51	405
OLFML3	AMPD1	P23109	396
OLFML3	PPARG	P37231	390
OLFML3	OGN	P20774	389

IntAct

18 interactions, top by confidence:

A	B	Type	Score
SDF2L1	OLFM2	psi-mi:“MI:0914”(association)	0.640
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
OLFML3	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
OLFML3	UQCR10	psi-mi:“MI:0915”(physical association)	0.400
OLFML3	MAP7D2	psi-mi:“MI:0915”(physical association)	0.400
DPAGT1	ALOX12B	psi-mi:“MI:0914”(association)	0.350
KMO	HSPA7	psi-mi:“MI:0914”(association)	0.350
C1orf54	QSOX1	psi-mi:“MI:0914”(association)	0.350
CLGN	TMEM131L	psi-mi:“MI:0914”(association)	0.350
LCN6	HIGD1C	psi-mi:“MI:0914”(association)	0.350
MFAP4	PROS1	psi-mi:“MI:0914”(association)	0.350
PATE1	AGRN	psi-mi:“MI:0914”(association)	0.350
CKMT2	OLFML3	psi-mi:“MI:0915”(physical association)	0.000
OLFML3	FEZ1	psi-mi:“MI:0915”(physical association)	0.000
OLFML3	SETDB1	psi-mi:“MI:0915”(physical association)	0.000
HSPB3	OLFML3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): MAP7D2 (Affinity Capture-MS), OLFML3 (Affinity Capture-MS), OLFML3 (Affinity Capture-MS), OLFML3 (Two-hybrid), OLFML3 (Two-hybrid), FEZ1 (Two-hybrid), SETDB1 (Two-hybrid), UQCR10 (Proximity Label-MS), OLFML3 (Affinity Capture-MS), OLFML3 (Affinity Capture-MS), MAP7D2 (Affinity Capture-MS), OLFML3 (Positive Genetic), OLFML3 (Cross-Linking-MS (XL-MS)), OLFML3 (Two-hybrid)

ESM2 similar proteins: A2BD09, B0BNI5, B5MFE9, D3Z7H8, O70624, O75326, O88632, P09531, P42917, P82350, Q0P3W2, Q0V9V5, Q0VCP3, Q13275, Q16586, Q25C36, Q28686, Q29RB4, Q2HJE5, Q2KHV9, Q2PT31, Q3UH93, Q4LFA9, Q594P2, Q64255, Q66H86, Q68BL7, Q6UWY5, Q6ZMI3, Q80WF4, Q80WL1, Q863A3, Q866N2, Q8BH02, Q8BHP7, Q8BK62, Q8BMF8, Q8IUL8, Q8IYS2, Q91X21

Diamond homologs: A2BD09, A4IIT5, A6QLD2, B0BNI5, B5MFE9, O70624, O88917, O88923, O88998, O94910, O95490, O95897, O97817, O97827, O97831, P63056, P63057, Q0P3W2, Q0V9V5, Q0VCP3, Q25C36, Q2PT31, Q3UZZ4, Q3V1G4, Q568Y7, Q594P2, Q62609, Q66H86, Q68BL7, Q68BL8, Q6UWY5, Q6UX06, Q80TR1, Q80TS3, Q863A3, Q866N2, Q8BHP7, Q8BK62, Q8BM13, Q8JZZ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

72 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

352 predictions. Top by Δscore:

Variant	Effect	Δscore
1:113979627:AGAGG:A	donor_loss	1.0000
1:113979628:GAG:G	donor_gain	1.0000
1:113979629:AGGT:A	donor_loss	1.0000
1:113979631:G:GA	donor_loss	1.0000
1:113979632:T:G	donor_loss	1.0000
1:113980494:G:GT	donor_gain	1.0000
1:113980585:G:T	donor_gain	1.0000
1:113980614:ACAG:A	donor_gain	1.0000
1:113980618:GT:G	donor_loss	1.0000
1:113980619:T:A	donor_loss	1.0000
1:113980932:T:A	acceptor_gain	1.0000
1:113980947:A:AG	acceptor_gain	1.0000
1:113980948:G:GG	acceptor_gain	1.0000
1:113980948:GACT:G	acceptor_gain	1.0000
1:113979631:G:GG	donor_gain	0.9900
1:113980256:T:A	acceptor_gain	0.9900
1:113980326:CTTCA:C	acceptor_loss	0.9900
1:113980327:TTCA:T	acceptor_loss	0.9900
1:113980328:TCA:T	acceptor_loss	0.9900
1:113980329:CAG:C	acceptor_loss	0.9900
1:113980330:A:G	acceptor_loss	0.9900
1:113980331:G:GA	acceptor_loss	0.9900
1:113980331:GGAAC:G	acceptor_gain	0.9900
1:113980494:G:T	donor_gain	0.9900
1:113980580:C:T	donor_gain	0.9900
1:113980598:G:GT	donor_gain	0.9900
1:113980612:TGAC:T	donor_gain	0.9900
1:113980934:T:TA	acceptor_gain	0.9900
1:113980945:TCA:T	acceptor_loss	0.9900
1:113980946:CA:C	acceptor_loss	0.9900

AlphaMissense

2610 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:113981020:T:A	W158R	1.000
1:113981020:T:C	W158R	1.000
1:113981400:G:C	W284C	1.000
1:113981400:G:T	W284C	1.000
1:113981022:G:C	W158C	0.999
1:113981022:G:T	W158C	0.999
1:113981096:T:G	F183C	0.999
1:113981114:T:C	F189S	0.999
1:113981206:T:G	Y220D	0.999
1:113981277:A:C	K243N	0.999
1:113981277:A:T	K243N	0.999
1:113981398:T:A	W284R	0.999
1:113981398:T:C	W284R	0.999
1:113981443:G:C	A299P	0.999
1:113981484:G:C	W312C	0.999
1:113981484:G:T	W312C	0.999
1:113981494:T:A	C316S	0.999
1:113981494:T:C	C316R	0.999
1:113981495:G:C	C316S	0.999
1:113981531:G:A	C328Y	0.999
1:113981532:T:G	C328W	0.999
1:113981642:T:G	F365C	0.999
1:113981707:T:A	W387R	0.999
1:113981707:T:C	W387R	0.999
1:113981709:G:C	W387C	0.999
1:113981709:G:T	W387C	0.999
1:113981015:G:A	G156D	0.998
1:113981095:T:C	F183L	0.998
1:113981096:T:C	F183S	0.998
1:113981097:C:A	F183L	0.998

dbSNP variants (sampled 300 via entrez): RS1000038435 (1:113980831 T>C,G), RS1000215173 (1:113978876 C>G), RS1002292470 (1:113980203 G>A,T), RS1002949728 (1:113978967 A>C,G), RS1003212430 (1:113978227 T>A,C), RS1003393145 (1:113978732 T>A), RS1004148338 (1:113981572 C>T), RS1004177716 (1:113981245 GGT>G), RS1004783262 (1:113981711 A>G,T), RS1005708130 (1:113978537 C>A,T), RS1006977701 (1:113979558 A>G), RS1007067184 (1:113979560 G>A), RS1007393744 (1:113978504 C>T), RS1007471531 (1:113978299 T>C), RS1010276533 (1:113979231 C>T)

Disease associations

OMIM: gene MIM:610088 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001762_676	Obesity-related traits	2.000000e-06
GCST004866_5	Alopecia areata	7.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005134	amino acid measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	8
bisphenol A	increases expression, affects cotreatment	5
Estradiol	affects cotreatment, increases expression	4
Genistein	affects cotreatment, increases expression	4
trichostatin A	affects cotreatment, increases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	3
Cyclosporine	decreases expression	3
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Resveratrol	increases expression, affects cotreatment, decreases expression	2
Arsenic Trioxide	decreases expression	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Zearalenone	increases expression	2
FR900359	decreases phosphorylation	1
bisphenol F	increases expression, affects cotreatment	1
daidzein	affects cotreatment, increases expression	1
testosterone undecanoate	decreases expression, affects cotreatment	1
terbufos	increases methylation	1
o,p’-DDT	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
glycitein	affects cotreatment, increases expression	1
corosolic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	decreases expression	1
Ethanol	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer